Cybersecurity and privacy risk assessment of point-of-care systems in healthcare: A use case approach
Contents
![]() | |
Names | |
---|---|
Preferred IUPAC name
2-Methylcyclohexyl methylphosphonofluoridate | |
Other names
Methyl cyclosarin[1]
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C8H16FO2P | |
Molar mass | 194.186 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
EA-1356 is an organophosphate nerve agent of the G-series.[2][3] It is highly resistant to enzymatic degradation in the body. [4] The nerve agent was tested at Edgewood Arsenal in Maryland (the "EA" in "EA-1356") among many other chemicals tested on humans. A novel enzyme was patented by the US Army in 2018 to break down EA-1356. It is a schedule 1 substance by the Chemical Weapons Convention standards. It is under the category of munitions of ML7.b.1.a.
References
- ^ Noga, M.; Michalska, A.; Jurowski, K. (2024). "The estimation of acute oral toxicity (LD(50)) of G-series organophosphorus-based chemical warfare agents using quantitative and qualitative toxicology in silico methods". Archives of Toxicology. doi:10.1007/s00204-024-03714-5. PMID 38493428.
- ^ Söderström MT, Ketola RA, Kostiainen O (1995). "Identification of some nerve agent homologues and dialkyl methylphosphonates by gas chromatography/Fourier transform infrared spectrometry". Fresenius' Journal of Analytical Chemistry. 352 (6): 550–556. doi:10.1007/BF00323072. S2CID 100910978.
- ^ Ellison DH (2008). Handbook of Chemical and Biological Warfare Agents (Second ed.). CRC Press. ISBN 978-0-849-31434-6.
- ^ US 10124043, Harvey SP, Guelta MA, McMahon LR, "Mutant OPAA enzymes with increased catalytic efficiency on organophosphorus compound EA1356", issued 13 November 2018, assigned to U.S. Army Edgewood Chemical Biological Center